EATG » HIV treatment

HIV treatment

HIV i-Base: HTB, special CROI issue

HIV Treatment Bulletin (HTB) is a community publication produced by HIV i-Base. As CROI is a conference that keeps on giving, this issue of HTB continues with further reports from…

Theratechnologies to seek regulatory approval of Trogarzo™ in Europe

Theratechnologies to seek regulatory approval of Trogarzo™ (ibalizumab) in Europe based on efficacy and safety data used for FDA approval MONTREAL, April 24, 2018 -- Theratechnologies Inc. (Theratechnologies) today announced…

The evolution of antiretroviral therapy: past, present, and future

On June 5th, 1981, the United States Centers for Disease Control and Prevention (CDC) published a Morbidity and Mortality Weekly Report (MMWR), describing five cases of a rare lung infection,…

Paul Sax: Latest DHHS guidelines for initial HIV therapy now include 5 choices, but really 2 are best

On March 28, the Department of Health and Human Services Guidelines issued an update to the HIV treatment guidelines, with a focus on the recent approval of bictegravir/TAF/FTC: BIC/TAF/FTC is…

Generic HIV medicines: boon or bust?

The advent of generic HIV medications in the 2000s had a dramatic effect on improving outcomes in developing countries with a high HIV/AIDS burden. Before that, death rates were skyrocketing…

HIV drug tenofovir alafenamide offers safety, noninferiority to abacavir

The array of streamlined drug regimens that treat HIV has been nothing short of lifesaving. As more options become available, patients and providers need to weigh the pros and cons…

Doravirine effective in treatment-naive adults with HIV

Doravirine, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), is as effective as ritonavir-boosted darunavir, a protease inhibitor, in treatment-naive adults infected with HIV-1, according to results from the DRIVE-FORWARD trial.…

First-line ART failure common among hospitalised HIV-positive people in sub-Saharan Africa

A large proportion of hospitalised HIV-positive people in sub-Saharan Africa have experienced the failure of first-line antiretroviral therapy (ART), according to a study published in the journal Clinical Infectious Diseases.…

India could shift from efavirenz to dolutegravir for HIV treatment – at no extra cost, new research suggests

Researchers recommend dolutegravir (DTG)‐based antiretrovirals should become the first option for HIV treatment in India, following a study into DTG’s cost-effectiveness. At the moment, India recommends efavirenz (EFV)‐based antiretroviral treatment…

TAF only superior to TDF when used with a boosting agent

The benefits of tenofovir alafenamide (TAF) over tenofovir disoproxil fumarate (TDF) may have been overstated, according to the results of a meta-analysis published in the Journal of Virus Eradication. It…

1 2 3 52